Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $22.3 million.

  • RxSight's Total Current Liabilities fell 153.28% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year decrease of 153.28%. This contributed to the annual value of $25.9 million for FY2024, which is 2379.08% up from last year.
  • Per RxSight's latest filing, its Total Current Liabilities stood at $22.3 million for Q3 2025, which was down 153.28% from $20.4 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Total Current Liabilities registered a high of $25.9 million during Q4 2024, and its lowest value of $9.2 million during Q3 2021.
  • For the 5-year period, RxSight's Total Current Liabilities averaged around $17.3 million, with its median value being $17.8 million (2022).
  • As far as peak fluctuations go, RxSight's Total Current Liabilities tumbled by 450.86% in 2021, and later soared by 7837.84% in 2022.
  • RxSight's Total Current Liabilities (Quarter) stood at $11.1 million in 2021, then surged by 55.61% to $17.2 million in 2022, then rose by 21.27% to $20.9 million in 2023, then rose by 23.79% to $25.9 million in 2024, then fell by 13.85% to $22.3 million in 2025.
  • Its Total Current Liabilities was $22.3 million in Q3 2025, compared to $20.4 million in Q2 2025 and $22.7 million in Q1 2025.